The Need for Transitional Coverage for Emerging Technologies (TCET)

March 28, 2022

For patients on Medicare, the majority of whom are over age 65, time matters. However, newly published research from the Stanford Byers Center for Biodesign shows that patients can wait up to 5 years after FDA authorization to access new medical technologies. Instead, a well-designed transitional coverage program could greatly accelerate patients’ access to care, while reducing the overall cost burden on our healthcare system. This program would also encourage innovation in areas of critically important unmet clinical needs.

The Duke-Margolis Center for Health Policy has recommended the addition of several key elements to a transitional coverage pathway, highlighting the need for early engagement between stakeholders to inform and guide evidence development and appropriate use of novel technologies.

Please join us to explore these findings and hear the perspectives of physicians, innovators and CMS stakeholders on this important initiative to advance patient care.

Our speakers and panelists include:
Josh Makower, MD, Director & Co-founder, Stanford Byers Center for Biodesign
Mark McClellan, MD, Director, Duke-Margolis Center for Health Policy
Joe Franklin, JD, PhD, Product Counsel, Verily Life Sciences
Louise Guy, President and Managing Partner, Argenta Advisors
Dirksen Lehman, JD, Corporate Vice President, Public Affairs, Edwards Lifesciences
Marianne Hamilton Lopez, PhD, Senior Research Director, Biomedical Innovation, Duke Margolis Center for Health Policy
Michael Mack, MD, Medical Director, Cardiothoracic Surgery, Baylor Scott and White Health
Parashar Patel, Senior Vice President Government Affairs & Market Access, Viewray
Sandra Waugh Ruggles, PhD, Assistant Director Innovation Fellowship, Stanford Byers Center for Biodesign
Kevin Schulman, MD, Professor of Medicine, CERC, Stanford University School of Medicine